Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation

"Dosage form: Capsule. Strength: 2.5 mg, 5 mg. Method of administration: Oral; Dose escalation: a fixed dose QD is planned, and all other dose levels and administration methods are temporary with the exception of the initial dose. Dose expansion: the dose and method of administration are conducted as discussed by the sponsor and investigators.~Medication cycle: Take orally under fasting condition every morning, with 21 days as a cycle (tentative), and continue taking until disease progression, or intolerable toxicity, or withdrawal of informed consent, or treatment with another antitumor drug, or the death of the subject, or loss to follow-up (whichever occurs earliest)."